Possible Cases of SARS-CoV-2 Reinfection In Pekanbaru, Indonesia
Keywords:
COVID-19, Indonesia, reinfection, SARS-CoV-2Abstract
Confirmed and possible reinfection cases of SARS-CoV-2 have been reported from various countries. Here we present two cases of possible SARS-CoV-2 reinfection in Pekanbaru, Indonesia. A 26 years old female and a 27 years old male healthcare workers were first confirmed by PCR with high Ct-value (>35) while presenting no or mild symptoms, respectively. In more than one month since the last negative test results, both patients developed typical COVID-19 symptoms; fever and anosmia. RT-PCR results for SARS-CoV-2 were positive with Ct-value less than 30. The timeframe between 1st and 2nd episode, negative test result between episodes, and epidemiological risk factor strengthened the possibility of reinfection. However, we did not have whole genome sequence (WGS) or viral viability data to further confirm reinfection with different viable virus. The requirement of viral WGS data to confirm true reinfection cases calls for investment in whole genome sequencing platform in public health laboratories. We encourage standardized definition of SARS-CoV-2 reinfection case in order to be able to investigate and observe such cases.References
Iwasaki A. What reinfection means for COVID-19. Lancet Infect Dis. 2020; (published online Oct 12, 2020). DOI: 10.1016/S1473-3099(20)30783-0
To KKW, Hung IFN, Ip JD, et al. 2020. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020; (published online Aug 25, 2020). DOI:10.1093/cid/ciaa1275
Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020;(published online Oct 12, 2020). DOI: 10.1016/S1473-3099(20)30764-7
van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2020; (published online Sep 5, 2020). DOI: 10.1093/cid/ciaa1330
Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, et al. COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America. SSRN. 2020; (published online Sep 8, 2020) [preprint]. DOI: 10.2139/ssrn.3686174
West J, Everden S, Nikitas N. A case of COVID-19 reinfection in the UK. Clin Med Dec. 2020. DOI: 10.7861/clinmed.2020-0912.
Duggan NM, Ludy SM, Shannon CB, Reisner AT, Wilcox SR. Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results. Am J Emerg Med. 2021; (published online Jul 4, 2020). DOI: 10.1016/j.ajem.2020.06.079
Akram L, Khan MHUR, Iqbal, Akram A. A case report of recurrent COVID-19 infection of a physician in Bangladesh: Re-infection or persistence infection? Bangladesh J Infect Dis. 2020;7(Suppl 2):S57-S60. DOI: 10.3329/bjid.v7i00.50164
Nachmias V, Fusman R, Mann S, Koren G. The first case of documented Covid-19 reinfection in Israel. IDCases 2020; 22: e00970. DOI: 10.1016/j.idcr.2020.e00970
Centers for Disease Control and Prevention. Common investigation protocol for suspected SARS-CoV-2 reinfection. 2020; (published online Oct 27, 2020)https://www.cdc.gov/coronavirus/2019-ncov/php/reinfection.html
Yahav D, Yelin D, Eckerle I, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2020; (published online Dec 4, 2020). DOI: 10.1016/j.cmi.2020.11.028
Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240. DOI:10.1126/sciimmunol.abe0240.
Jeewandara C, Jayathilaka D, Gomes L, et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illnes. Sci Rep. 2021; 11(1): 2062. DOI: 10.1038/s41598-021-81629-2.
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020; 383(11): 1085-1087. DOI: 10.1056/NEJMc2025179.
Choe PG, Kim K-H, Kang CK, et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis. 2021;(published online Dec 22, 2020). DOI: 10.3201/eid2703.204543
Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memomry persists after mild COVID-19. Cell. 2021;184(1):169-83.e17. DOI: 10.1016/j.cell.2020.11.029
Kim YI, Kim SM, Park SJ, et al. Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission, Emerg Microbes Infect. 2021. DOI: 10.1080/22221751.2021.1872352
Kwong JC, Mccallum N, Sintchenko V, Howden BP. Whole genome sequencing in clinical and public health microbiology. Pathology. 2015;47(3):199-210.
Köser CU, Ellington MJ, Cartwright EJP, et al. Routine use of microbial whole genome sequencing in diagnostic and public health laboratory. Plos Pathog. 2021;8(8):e1002824.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
